Skip to main content
Premium Trial:

Request an Annual Quote

Myconostica Gets OK to Sell Fungal Dx in Canada

NEW YORK (GenomeWeb News) – Medical diagnostic company Myconostica said yesterday that it has received a license from Health Canada to sell its Aspergillus molecular diagnostic test in Canada.

Myconostica's MycAssay Aspergillus detects Aspergillus DNA in lower respiratory tract samples. Results of the test aid physicians in diagnosing immunocompromised patients suspected of having an infection caused by the fungus.

When MycAssay is used in conjunction with Myconostica's extraction system, MycXtra, a result can be obtained within three hours of sample receipt, the company said.

In conjunction with the announcement, Myconostica, based in Manchester, UK, also said that it has signed an agreement with Inverness Medical Canada, a subsidiary of Inverness Medical Innovations, to exclusively distribute Myconostica's products in Canada.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.